NewsBenzingaGuggenheim ribadisce il rating Buy su Oruka Therapeutics, mantiene il target di prezzo di 200 dollari Guggenheim ribadisce il rating Buy su Oruka Therapeutics, mantiene il target di prezzo di 200 dollari Benzinga 2026.10.27 13:37 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says